Adial Pharmaceuticals (ADIL) Total Current Liabilities (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Total Current Liabilities of $1.5 million for Q1 2026, up 8.1% sequentially from $1.4 million in Q4 2025, and up 100.99% YoY from $751327.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Total Current Liabilities (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Total Current Liabilities for 10 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Total Current Liabilities rose 100.99% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 100.99% YoY) and the FY2025 annual result came in at $1.4 million, up 43.15% from the prior year.
- Total Current Liabilities advanced to $1.5 million in Q1 2026 per ADIL's latest filing, from $1.4 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $2.2 million in Q1 2022 and troughed at $322173.0 in Q2 2024.
- A 5-year average of $1.1 million and a median of $975858.0 in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities sank 75.27% in 2023, then jumped 114.92% in 2025.
- Over 5 years, Total Current Liabilities stood at $1.8 million in 2022, then slumped by 63.53% to $653076.0 in 2023, then soared by 49.42% to $975858.0 in 2024, then surged by 43.15% to $1.4 million in 2025, then advanced by 8.1% to $1.5 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $1.5 million, $1.4 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 5.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 604,524.00 |
| Mar 31, 2025 | 751,327.00 |
| Dec 31, 2024 | 975,858.00 |
| Sep 30, 2024 | 537,303.00 |
| Jun 30, 2024 | 322,173.00 |
| Mar 31, 2024 | 595,203.00 |
| Dec 31, 2023 | 653,076.00 |
| Sep 30, 2023 | 813,371.00 |
| Jun 30, 2023 | 461,752.00 |
| Mar 31, 2023 | 1.80 Mn |
| Dec 31, 2022 | 1.79 Mn |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 1.87 Mn |
| Mar 31, 2022 | 2.17 Mn |
| Dec 31, 2021 | 2.72 Mn |
| Sep 30, 2021 | 1.96 Mn |
| Jun 30, 2021 | 2.21 Mn |